Prime Editing for p47phox-Deficient CGD
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events - including heart attack, stroke, and cardiovascular death - in individuals with...
- The SELECT trial followed participants for an average of 3.4 years.
- This study primarily impacts individuals with obesity *and* pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The study, involving over 17,600 participants, initially aimed to determine if semaglutide could reduce the risk of these events, but the results showed a statistically notable, though modest, increase in risk within the treatment group.This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Key findings and Data Breakdown
The SELECT trial followed participants for an average of 3.4 years. The primary composite outcome of nonfatal myocardial infarction,nonfatal stroke,or cardiovascular death occurred in 6.5% of participants receiving semaglutide versus 5.8% in the placebo group. This translates to a hazard ratio of 1.13, indicating a 13% increased risk. Importantly,the trial population consisted of adults with a body mass index (BMI) of 27 or higher,established cardiovascular disease (such as prior heart attack or stroke),and diabetes or obesity. The study did *not* include individuals without pre-existing cardiovascular conditions.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Myocardial Infarction, Stroke, or CV Death) | 6.5 | 5.8 | 1.13 |
| Myocardial Infarction | 3.4 | 2.9 | 1.17 |
| Stroke | 2.8 | 2.2 | 1.27 |
| Cardiovascular Death | 1.2 | 0.9 | 1.34 |
Who is Affected and Why This Matters
This study primarily impacts individuals with obesity *and* pre-existing cardiovascular disease. It does *not* suggest that semaglutide is inherently risky for everyone. Though, it necessitates a more cautious approach to prescribing these medications to patients with known heart conditions. The findings raise questions about potential mechanisms driving this increased risk, including effects on blood pressure, lipid profiles, and inflammation. The widespread use of semaglutide for weight loss, even in individuals without cardiovascular disease, means that a larger population is being exposed to the drug, warranting further investigation into long-term cardiovascular effects.
timeline of Semaglutide Research and Approval
Semaglutide was initially approved by the FDA in December 201